Carcinogenicity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Numerous analogues and derivatives of DMT are known. Some examples include tryptamine (T), N-methyltryptamine (NMT), serotonin (5-hydroxytryptamine; 5-HT), psilocin (4-HO-DMT), psilocybin (4-PO-DMT), 4-AcO-DMT (psilacetin), 4-PrO-DMT, bufotenin (5-HO-DMT or N,N-dimethylserotonin), and 5-MeO-DMT (mebufotenin; N,N,O-trimethylserotonin). Some further examples include methylethyltryptamine (MET), diethyltryptamine (DET), methylpropyltryptamine (MPT), dipropyltryptamine (DPT), methylisopropyltryptamine (MiPT), diisopropyltryptamine (DiPT), methylallyltryptamine (MALT), diallyltryptamine (DALT), and pyr-T (N,N-tetramethylenetryptamine) and their derivatives. Some lesser-known DMT derivatives include 1-methyl-DMT, lespedamine (1-MeO-DMT), 2-methyl-DMT, 4-methyl-DMT, 4-MeO-DMT, 4-fluoro-DMT, 5-methyl-DMT, 5-ethyl-DMT, 5-TFM-DMT, 5-EtO-DMT, 5-TFMO-DMT, 5-fluoro-DMT, 5-chloro-DMT, 5-bromo-DMT, 6-fluoro-DMT, 5,6-dibromo-DMT, 4,5-MDO-DMT, 4,5-DHP-DMT, 5,6-MDO-DMT, 5-MeS-DMT, 6-methyl-DMT, 6-HO-DMT, 6-MeO-DMT, 7-methyl-DMT, 7-MeO-DMT, NBoc-DMT (NB-DMT), α,N,N-TMT (α-Me-DMT), and α,N,N,O-TeMS (5-MeO-α-Me-DMT). Cyclized tryptamines containing DMT in their chemical structures include ibogalogs like ibogainalog and tabernanthalog; iboga alkaloids like ibogaine and noribogaine; lysergamides like ergine (LSA) and lysergic acid diethylamide (LSD); and partial ergolines and lysergamides like N-DEAOP-NMT, 10,11-seco-LSD, RU-28306 (4,α-methylene-DMT), RU-28251 (4,α-methylene-DPT), Bay R 1531 (LY-197206; 4,α-methylene-5-MeO-DPT), and NDTDI (8,10-seco-LSD), among others.
=== 1996 === 8 September The Mystery of the Cocaine Mummies, about pre-Columbian transoceanic contact theories; German toxicologist Svetlana Balabanova made a discovery in a Munich museum; Svetlana, of the Institute of Forensic Science in Ulm, had invented tests for substances in hair and sweat; people did not believe her; toxicologist John Henry of Guy's Hospital; Egyptologist Ann Rosalie David made independent tests at Manchester Museum; Alfred Grimm of the Egyptian Museum in Munich - Staatliche Sammlung für Ägyptische Kunst; Karnak in Egypt; a French TF1 broadcast in 1981; Michelle Lescot of the National Museum of Natural History, France; Nasri Iskander, chief curator of the Egyptian Museum in Cairo; botanist Sandy Knapp of the Natural History Museum, London; John Baines (Egyptologist); anthropologist Alice Beck Kehoe of Marquette University, and early transatlantic ocean crossings; Martin Bernal of Cornell University. Narrated by Robin Ellis, produced by Hilary Lawson, directed by Sarah Marris, made by TVF 15 September The Great Leveller, about psychosomatic medicine, and how work affects our health, and research on health equity carried out by Richard G.
An alternative approach to the identification and quantification of patient samples is through the use of mass spectrometry. This approach offers excellent precision and sensitivity in the identification, characterization and quantification of metabolites in multiple patient sample types, such as blood and urine. The mass spectrometry (MS) approach is typically coupled to gas chromatography (GC), in GC-MS or liquid chromatography (LC), in LC-MS, which aid in initially separating out the metabolite components within complex sample mixtures, and can allow for the isolation of particular metabolite subsets for analysis. GC-MS can provide relatively precise quantification of metabolites, as well as chemical structural information that can be compared to pre-existing chemical libraries. GC-MS can be conducted in a relatively high-throughput manner (greater than 100 samples per day) with greater detection sensitivity than NMR analysis. A limitation of GC-MS for this application, however, is that processed metabolite components must be readily volatilized for sample processing. LC-MS initially separates out the components of a sample mixture based on properties such as hydrophobicity, before processing them for identification and quantification by mass spectrometry (MS). Overall, LC-MS is an extremely flexible method for processing most compound types in a somewhat high-throughput manner (20-100 samples a day), also with greater sensitivity than NMR analysis. For both GC-MS and LC-MS there are limitations in the reproducibility of metabolite quantification.
Sources: en.wikipedia.org
Also stronger than the Erdős–Mordell inequality is the following: Let D, E, F be the orthogonal projections of P onto BC, CA, AB respectively, and H, K, L be the orthogonal projections of P onto the tangents to the triangle's circumcircle at A, B, C respectively. Then
A study by Keyes found that there are major costs of depression, which 14% of adults experience annually: it impairs social roles; it costs billions each year due to work absenteeism, diminished productivity, and healthcare costs; finally, depression accounts for at least one-third of suicides. Therefore, it is important to study flourishing to learn about what is possible if issues such as depression are tackled and how the ramifications of focusing on the positive make life better not just for one person, but also for others around them. Flourishing has significant positive aspects magnified when compared to languishing adults and when languishing adults are compared to depressed adults, as explained by Keyes. For example, languishing adults have the same amount of chronic disease as those that are depressed whereas flourishing adults are in exceptionally better physical health. Languishing adults miss as many days at work as depressed adults and, in fact, visit doctors and therapists more than depressed adults.
Many marine organisms use chemical defenses to deter predators. For example, some crustaceans and mesograzers, such as the Pseudamphithoides incurvaria, use toxic algae and seaweeds as a shield against predation by covering their bodies in these plants. These plants produce phycotoxins, diterpenes such as pachydictyol-A and dictyol-E, which have been shown to deter predators. Demonstrating this symbiotic relationship are cyanobacteria and shrimp. The snapping shrimp Alpheus frontalis has been observed in utilizing Moorena bouillonii, a cyanobacterium, for shelter and food. M. bouillonii produces compounds that are toxic to other marine organisms and coral but its relationship with A. frontalis demonstrates the use of M. bouillonii as a deterrent and shelter to protect A. frontalis. Other marine organisms produce chemicals endogenously to defend themselves. For example, the finless sole (Pardachirus marmoratus) produces a toxin that paralyzes the jaws of would-be predators. Many zoanthids produce potent toxins, such as palytoxin, which is one of the most poisonous known substances. Some species of these zooanthids are very brightly colored, which may be indicative of aposematic defense. Another defensive measure that involves chemical ecology and marine ecology is the bobtail squid's light organ. The bobtail which is located in Hawaii contains a light organ that houses consumed bacterium Vibrio fischeri, V. fisheri bacterium utilizes quorum sensing to indicate expression for bioluminescence, for down welling light intensity.
Traditional non-alcoholic beverage companies, like PepsiCo, Fuze Beverage, and The Coca-Cola Company. Major food companies, such as Nestlé, Altria, Kraft Foods, General Mills, and the Campbell Soup Company. Smaller-scaled private companies and specialized companies like POM Wonderful. Agricultural cooperatives, such as Ocean Spray and Sunsweet Growers.
Sources: en.wikipedia.org
=== Disease === Chronic Granulomatous Disease is an inherited disease of human neutrophils, wherein NOX2 is defective. Phagocytosis may still occur, but without proper functioning NOX2, there is no superoxide production, and therefore no respiratory burst. The bacterial infection is not cleared.
== Adverse effects == Side effects of mescaline include fatigue, weakness, impaired concentration, restlessness, tension, anxiety, panic, and social discomfort and avoidance, headache, pupil dilation, nausea, vomiting, sweating, trembling, discomfort, feeling hot or cold, palpitations, chest and neck pains, shortness of breath, increased heart rate and blood pressure, and increased body temperature, among others. Nausea and vomiting are important dose-limiting side effects of mescaline and occur at greater rates than with other psychedelics like LSD and psilocybin. High doses of mescaline, such as 800 mg and above, are not well-tolerated due to substantial nausea and vomiting. On the other hand, mescaline appears to induce less fear and anxiety than LSD and psilocybin even at equivalent doses.
Other attempts to extend ceramic petrography include the use of automated image analysis, the palaeontological analysis of microscopic fossils within ceramic thin sections and the combined statistical classification of petrographic and chemical data from artefacts. Examples of Ceramic Petrography in archaeological settlements:
Bromazolam (XLI-268) is a triazolobenzodiazepine (TBZD) which was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam and has similar sedative and anxiolytic effects to it and other benzodiazepines. Bromazolam is a non subtype selective agonist at the benzodiazepine site of GABAA receptors, with a binding affinity of 2.81 nM at the α1 subtype, 0.69 nM at α2 and 0.62 nM at α5. The "common" dosage range for users of bromazolam was reported to be 1–2 mg, suggesting its potency is similar to alprazolam.
7 November – Scottish ministers say they will not comply with UK government legislation to enforce a 40% minimum service during strike action, with Neil Gray, the Cabinet Secretary for Wellbeing Economy, Fair Work and Energy, describing the plans, outlined in the Strikes (Minimum Service Levels) Act, as "appalling". 9 November – First Minister Humza Yousaf defends £11,000 worth of roaming charges accrued Health Secretary Michael Matheson as he used his parliamentary iPad during a holiday to Morocco as a "legitimate parliamentary expense". Matheson has blamed the charges on an "outdated sim card". 10 November – Around 500 employees of Scottish Water belonging to the GMB, Unite and Unison trade unions, begin a four-day strike over a pay dispute. Scotland's Health Secretary, Michael Matheson, agrees to pay back the £11,000 of roaming charges he built up while using his iPad during a holiday in Morocco. 11 November – Edinburgh will become the first city in Scotland to make pavement parking illegal, starting in January 2024. 12 November – NHS Greater Glasgow and Clyde, Scotland's largest health board, is named in a corporate homicide investigation following the deaths of four patients at a Glasgow hospital. 14 November – Seven members of a paedophile gang are found guilty of running a child sex abuse ring in Glasgow, described by the NSPCC as one of the worst cases of its kind in decades. Scottish Conservatives threaten to table a vote of no confidence in Health Secretary Michael Matheson if he refuses to hand over his ministerial iPad.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.